Subscribe
scotus-istock-482156434
renaschild / iStockphoto.com
26 June 2018Americas

SCOTUS agrees to hear on-sale bar battle

The US Supreme Court has agreed to hear a dispute over whether confidential sales of an invention can trigger the on-sale bar and invalidate a patent under the America Invents Act (AIA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Helsinn seeks SCOTUS review of patent case
5 March 2018   Swiss-based pharmaceutical company Helsinn Healthcare has filed a petition for writ of certiorari with the US Supreme Court.
Americas
Federal Circuit reverses district court’s on-sale bar ruling
2 May 2017   The US Court of Appeals for the Federal Circuit ruled yesterday that a patent is invalid if the invention was sold before being patented, even if the invention was not publicly disclosed.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Helsinn seeks SCOTUS review of patent case
5 March 2018   Swiss-based pharmaceutical company Helsinn Healthcare has filed a petition for writ of certiorari with the US Supreme Court.
Americas
Federal Circuit reverses district court’s on-sale bar ruling
2 May 2017   The US Court of Appeals for the Federal Circuit ruled yesterday that a patent is invalid if the invention was sold before being patented, even if the invention was not publicly disclosed.

More on this story

Americas
Helsinn seeks SCOTUS review of patent case
5 March 2018   Swiss-based pharmaceutical company Helsinn Healthcare has filed a petition for writ of certiorari with the US Supreme Court.
Americas
Federal Circuit reverses district court’s on-sale bar ruling
2 May 2017   The US Court of Appeals for the Federal Circuit ruled yesterday that a patent is invalid if the invention was sold before being patented, even if the invention was not publicly disclosed.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York